@article{25775f69ddd24521ac8cf952627e7ed0,
title = "Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment",
abstract = "Background: Data are limited regarding the risk of hepatitis C virus (HCV) reinfection after treatment-induced sustained virologic response (SVR) in patients on haemodialysis. Aims: To assess the risk of HCV reinfection among patients on haemodialysis with treatment-induced SVR. Methods: Patients on haemodialysis patients who achieved SVR12 with interferon (IFN) or direct-acting antiviral (DAA)-based treatment received follow-up at SVR24 and then biannually with HCV RNA measurements. HCV reinfection was defined as the resurgence of viremia by different viral strains beyond SVR12. The low-risk general population who achieved SVR12 and who underwent the same post-SVR12 surveillance served as the reference group. Crude reinfection rates per 100 person-years (PYs) were calculated. Multivariate Cox regression analysis was performed to estimate the relative risk of HCV reinfection between the two groups. Results: We recruited 374 patients on haemodialysis and 1571 reference patients with a mean post-SVR12 follow-up of 4.7 and 6.1 years. All haemodialysis patients who achieved SVR12 also achieved SVR24. The incidence rates of HCV reinfection were 0.23 per 100 PYs (95% confidence interval [CI]: 0.09-0.59) in haemodialysis patients and 0.16 per 100 PYs (95% CI: 0.10-0.26) in the reference group. The risk of HCV reinfection in patients on haemodialysis was comparable to that in the reference patients (hazard ratio [HR]: 1.39; 95% CI: 0.44-4.38, P = 0.57). Conclusions: The risk of HCV reinfection in patients on haemodialysis who achieve SVR12 is low and comparable to that in the low-risk general population. HCV microelimination in this special population is feasible once universal screening and scaled-up treatment are implemented.",
author = "Liu, {Chen Hua} and Peng, {Cheng Yuan} and Kao, {Wei Yu} and Yang, {Sheng Shun} and Shih, {Yu Lueng} and Lin, {Chin Lin} and Tsai, {Meng Kun} and Lee, {Chih Yuan} and Chang, {Chun Chao} and Wu, {Jo Hsuan} and Liu, {Chun Jen} and Su, {Tung Hung} and Tseng, {Tai Chung} and Chen, {Pei Jer} and Kao, {Jia Horng}",
note = "Funding Information: Ministry of Science and Technology, Taiwan (MOST) (110‐2314‐B‐002‐172) and National Taiwan University Hospital (110‐P07). Funding Information: This study was funded in full by Ministry of Science and Technology, Taiwan (MOST) (110‐2314‐B‐002‐172) and National Taiwan University Hospital (110‐P07). Declaration of funding interests: Funding Information: Ministry of Science and Technology, Taiwan (MOST) (110-2314-B-002-172) and National Taiwan University Hospital (110-P07). The authors thank Hui-Ju Lin and Pin-Chin Huang for clinical data management; the 7th Core Lab of National Taiwan University Hospital and the 1st Common Laboratory of National Taiwan University Hospital, Yun-Lin Branch for instrumental and technical support. Declaration of personal interests: CHL has served as a speaker for Abbott, has served as a speaker, a consultant and an advisory board member for Abbvie, Gilead Sciences, and Merck Sharp & Dohme, and has received research funding from Abbvie, Gilead Sciences, and Merck Sharp & Dohme. JHK has served as a speaker, a consultant and an advisory board member for Abbott, Abbvie, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, and Roche. All the other authors declare no competing interests. Declaration of funding interests: This study was funded in full by Ministry of Science and Technology, Taiwan (MOST) (110-2314-B-002-172) and National Taiwan University Hospital (110-P07). Publisher Copyright: {\textcopyright} 2021 John Wiley & Sons Ltd",
year = "2022",
month = feb,
doi = "10.1111/apt.16697",
language = "English",
volume = "55",
pages = "434--445",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "4",
}